- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00547352
Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection
October 18, 2007 updated by: Eli Lilly and Company
Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference
To determine if men with problems getting and keeping an erection prefer treatment with tadalafil or sildenafil.
Study Overview
Study Type
Interventional
Enrollment (Actual)
160
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- History of erection problems
- Anticipate a monogamous female sexual relationship
- Abstain from other erection treatments throughout the study
- Currently use sildenafil
Exclusion Criteria:
- Other primary sexual disorders
- History of radical prostatectomy or other pelvic surgery that affected being able to have an erection
- History of penile implant or clinically significant penile deformity.
- Nitrate use
- Certain heart problems
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
sildenafil treatment for at least 10 weeks prior to a 1 week wash out
|
Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
|
Active Comparator: 2
Tadalafil treatment for 8 weeks following the 1 week washout period.
|
20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient choice of drug at visit 5
Time Frame: 14-15 weeks
|
14-15 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PAIRS self-administered scale scores
Time Frame: 14-15 weeks
|
14-15 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2004
Study Completion (Actual)
June 1, 2005
Study Registration Dates
First Submitted
October 18, 2007
First Submitted That Met QC Criteria
October 18, 2007
First Posted (Estimate)
October 22, 2007
Study Record Updates
Last Update Posted (Estimate)
October 22, 2007
Last Update Submitted That Met QC Criteria
October 18, 2007
Last Verified
October 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9152 (Other Identifier: CTEP)
- H6D-KL-S002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impotence
-
National Taiwan University HospitalAbbottUnknown
-
University Hospital, MontpellierCompletedPainful Hip | Fonctional Impotence After Minor Trauma (Fall)France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedImpotenceGreece, Italy, Spain, Russian Federation, Canada, Israel, United Kingdom, France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Rambam Health Care CampusUnknown
-
Rio de Janeiro State UniversityCompletedErectile Dysfunction | Impotence
-
University Hospital, SaarlandNovartisWithdrawn
-
PfizerCompletedImpotenceNorway, United Kingdom
-
Eli Lilly and CompanyICOS CorporationCompletedImpotenceUnited States, Austria, France, Germany, Mexico
-
Boston Scientific CorporationCompletedErectile Dysfunction | ImpotenceUnited States, Canada
Clinical Trials on sildenafil
-
University of PennsylvaniaWalter Reed National Military Medical CenterRecruiting
-
Rambam Health Care CampusUnknown
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); PfizerCompleted
-
Northwestern UniversityCompletedHand Foot Skin ReactionUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedErectile DysfunctionSingapore
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
The Cleveland ClinicCompletedPulmonary Hypertension | Diffuse Parenchymal Lung DiseaseUnited States
-
iX Biopharma Ltd.Linear Clinical ResearchCompletedErectile DysfunctionAustralia
-
Rigshospitalet, DenmarkGlostrup University Hospital, CopenhagenCompletedBecker Muscular DystrophyDenmark
-
N4 Pharma UK Ltd.BDD Pharma LtdCompleted